 |
49 Diseases |  |
64 Trials |
|
64 Trials |  |
670 News |  |
| «1234567891011» |
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date: ECOG-ACRIN E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 21, 2023
P3, N=488, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Sep 2025 --> Jul 2023 | Trial primary completion date: Sep 2025 --> Jul 2023
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment open: Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (clinicaltrials.gov) - Mar 20, 2023
P3, N=348, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Sep 2025 --> Jul 2023 | Trial primary completion date: Sep 2025 --> Jul 2023 Active, not recruiting --> Recruiting
- || Monjuvi (tafasitamab-cxix) / MorphoSys, Xencor, Incyte, Specialised Therap, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment open: Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 17, 2023
P2, N=30, Recruiting, Sponsor: University of Washington
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Venclexta (venetoclax) / Roche, AbbVie, DS-1594 / Daiichi Sankyo
Trial completion date, Trial primary completion date, Combination therapy: DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 16, 2023
P1/2, N=20, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Trial completion date: Nov 2022 --> Nov 2024 | Trial primary completion date: Nov 2022 --> Nov 2024
- | Ukoniq (umbralisib) / TG Therap, Gazyva (obinutuzumab) / Roche, Biogen
Enrollment open: SWOG S1608: Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma (clinicaltrials.gov) - Mar 14, 2023
P2, N=95, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Nov 2022 --> Nov 2024 | Trial primary completion date: Nov 2022 --> Nov 2024 Suspended --> Recruiting
- | revumenib (SNDX-5613) / Syndax Pharma
New P2 trial, Combination therapy: A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia (clinicaltrials.gov) - Mar 9, 2023
P2, N=78, Not yet recruiting, Sponsor: Children's Oncology Group
- | Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma, Erleada (apalutamide) / J&J
Biomarker, Trial completion date, Trial primary completion date, Metastases: NCI-2018-01054: Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Mar 8, 2023
P2, N=60, Suspended, Sponsor: M.D. Anderson Cancer Center
Suspended --> Recruiting Trial completion date: Oct 2022 --> Apr 2024 | Trial primary completion date: Oct 2022 --> Apr 2024
- | dasatinib / Generic mfg.
Trial completion date: Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 7, 2023
P2, N=97, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Oct 2022 --> Apr 2024 | Trial primary completion date: Oct 2022 --> Apr 2024 Trial completion date: Jan 2023 --> Jan 2024
- | prednisone delayed-release tablet / Generic mfg.
Journal: Evaluaci (Pubmed Central) - Mar 4, 2023
Trial completion date: Jan 2023 --> Jan 2024 Although none of the measures applied through the FMEA made the failure mode impossible, they made it more detectable and less frequent and reduced the RPN for each failure mode; however, a periodic update of the process is necessary.
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date, Combination therapy: AALL1731: A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 1, 2023
P3, N=6720, Suspended, Sponsor: National Cancer Institute (NCI)
Although none of the measures applied through the FMEA made the failure mode impossible, they made it more detectable and less frequent and reduced the RPN for each failure mode; however, a periodic update of the process is necessary. Trial completion date: Sep 2029 --> Dec 2029 | Trial primary completion date: Sep 2029 --> Dec 2029
- | Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma, Erleada (apalutamide) / J&J
Trial primary completion date, Metastases: Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer (clinicaltrials.gov) - Feb 27, 2023
P2, N=60, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Sep 2029 --> Dec 2029 | Trial primary completion date: Sep 2029 --> Dec 2029 Trial primary completion date: Oct 2022 --> Oct 2023
- | Rituxan (rituximab) / Roche
Trial completion date: Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Feb 21, 2023
P2, N=349, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Oct 2022 --> Oct 2023 Trial completion date: Dec 2022 --> Dec 2023
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment closed: Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (clinicaltrials.gov) - Feb 17, 2023
P3, N=348, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2022 --> Dec 2023 Suspended --> Active, not recruiting
- | abiraterone acetate / Generic mfg.
Biomarker, Trial completion date, Trial primary completion date: Pharmacogenomics IND EXEMPT SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms (clinicaltrials.gov) - Feb 14, 2023
P1, N=20, Active, not recruiting, Sponsor: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Suspended --> Active, not recruiting Trial completion date: Mar 2022 --> Oct 2023 | Trial primary completion date: Mar 2022 --> Oct 2023
- | Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Entyvio (vedolizumab) / Takeda
Trial completion date, Trial primary completion date, Checkpoint inhibition: NCI-2018-03437: Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer (clinicaltrials.gov) - Feb 13, 2023
P1/2, N=800, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Mar 2022 --> Oct 2023 | Trial primary completion date: Mar 2022 --> Oct 2023 Trial completion date: Jan 2023 --> Oct 2025 | Trial primary completion date: Jan 2023 --> Oct 2025
- | thioguanine / Generic mfg., dasatinib / Generic mfg.
Trial primary completion date: AALL1131: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations (clinicaltrials.gov) - Jan 31, 2023
P3, N=5937, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jan 2023 --> Oct 2025 | Trial primary completion date: Jan 2023 --> Oct 2025 Trial primary completion date: Dec 2023 --> Dec 2022
- | cyclophosphamide / Generic mfg.
Trial completion, Trial completion date: Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma (clinicaltrials.gov) - Jan 31, 2023
P3, N=53, Completed, Sponsor: Children's Oncology Group
Trial primary completion date: Dec 2023 --> Dec 2022 Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Dec 2022
- | Akeega (abiraterone/niraparib) / J&J, Zejula (niraparib) / GSK, J&J
New P2 trial, Metastases: CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations (clinicaltrials.gov) - Jan 18, 2023
P2, N=30, Not yet recruiting, Sponsor: Mayo Clinic
- | nelarabine / Generic mfg.
Trial completion date, Trial primary completion date: Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Jan 13, 2023
P2, N=160, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Dec 2022 Trial completion date: Oct 2022 --> Oct 2023 | Trial primary completion date: Oct 2022 --> Oct 2023
- | Ukoniq (umbralisib) / TG Therap, Gazyva (obinutuzumab) / Roche, Biogen
Trial completion date, Trial primary completion date: SWOG S1608: Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma (clinicaltrials.gov) - Jan 10, 2023
P2, N=95, Suspended, Sponsor: National Cancer Institute (NCI)
Trial completion date: Oct 2022 --> Oct 2023 | Trial primary completion date: Oct 2022 --> Oct 2023 Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Dec 2023 --> Jun 2024
- | Ukoniq (umbralisib) / TG Therap, Gazyva (obinutuzumab) / Roche, Biogen
Trial completion date, Trial primary completion date: SWOG S1608: Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma (clinicaltrials.gov) - Jan 9, 2023
P2, N=95, Suspended, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Dec 2023 --> Jun 2024 Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer, Opdivo (nivolumab) / BMS
New P3 trial, Immuno-oncology: AHOD2131: A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab (clinicaltrials.gov) - Jan 9, 2023
P3, N=1875, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | thioguanine / Generic mfg., dasatinib / Generic mfg.
Trial primary completion date: AALL1131: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations (clinicaltrials.gov) - Jan 4, 2023
P3, N=5956, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023 Trial primary completion date: Dec 2022 --> Dec 2023
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial suspension: Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (clinicaltrials.gov) - Jan 3, 2023
P3, N=348, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2022 --> Dec 2023 Recruiting --> Suspended
- || prednisone delayed-release tablet / Generic mfg.
El dalsy está bueno, lo q sabía a rayos era el epitetal🤢 (Twitter) - Dec 22, 2022
- ||| prednisone delayed-release tablet / Generic mfg.
El secreto del Frenadol es su sabor (sabe a rayos caducados y mohosos). El cuerpo se cura para que dejes de darle semejante ... (Twitter) - Dec 21, 2022
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial suspension, Combination therapy: AALL1731: A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 21, 2022
P3, N=6720, Suspended, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended Recruiting --> Suspended
- | Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Trial completion date, Trial primary completion date: NCI-2017-00596: Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 21, 2022
P2, N=80, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Suspended Trial completion date: Nov 2021 --> Nov 2023 | Trial primary completion date: Nov 2021 --> Nov 2023
- | Zolinza (vorinostat) / Merck (MSD), Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion date: Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas (clinicaltrials.gov) - Dec 20, 2022
P2, N=107, Completed, Sponsor: National Cancer Institute (NCI)
Trial completion date: Nov 2021 --> Nov 2023 | Trial primary completion date: Nov 2021 --> Nov 2023 Trial completion date: Sep 2021 --> May 2022
- | Zynyz (retifanlimab-dlwr) / Incyte, Monjuvi (tafasitamab-cxix) / Incyte
Enrollment open, Combination therapy: Tafasitamab, Retifanlimab, and Rituximab in Combination With Chemotherapy (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) for the Treatment of Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Dec 9, 2022
P1/2, N=35, Recruiting, Sponsor: University of Washington
Trial completion date: Sep 2021 --> May 2022 Not yet recruiting --> Recruiting
- | Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Arzerra (ofatumumab) / Novartis, Genmab, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion date, Trial primary completion date, Combination therapy: NCI-2014-01707: Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 8, 2022
P2, N=40, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Trial completion date: Dec 2022 --> Jun 2023 | Trial primary completion date: Dec 2022 --> Jun 2023
- | Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Trial completion date, Trial primary completion date: Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 6, 2022
P1, N=24, Active, not recruiting, Sponsor: University of Washington
Trial completion date: Dec 2022 --> Jun 2023 | Trial primary completion date: Dec 2022 --> Jun 2023 Trial completion date: Feb 2026 --> Oct 2027 | Trial primary completion date: Feb 2024 --> Oct 2022
- | Opdivo (nivolumab) / Ono Pharma, BMS
Trial completion date, Trial primary completion date, Combination therapy: Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (clinicaltrials.gov) - Dec 1, 2022
P3, N=192, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Feb 2026 --> Oct 2027 | Trial primary completion date: Feb 2024 --> Oct 2022 Trial completion date: Jun 2028 --> Dec 2028 | Trial primary completion date: Jun 2028 --> Dec 2028
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date, Combination therapy: AALL1731: A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 1, 2022
P3, N=6720, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2028 --> Dec 2028 | Trial primary completion date: Jun 2028 --> Dec 2028 Trial completion date: Mar 2028 --> Sep 2029 | Trial primary completion date: Mar 2028 --> Sep 2029
- | methylprednisolone sodium succinate / Generic mfg., prednisone delayed-release tablet / Generic mfg.
Trial completion date, Trial primary completion date: High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors (clinicaltrials.gov) - Nov 14, 2022
P1/2, N=25, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Mar 2028 --> Sep 2029 | Trial primary completion date: Mar 2028 --> Sep 2029 Trial completion date: Jul 2022 --> Jul 2024 | Trial primary completion date: Jul 2022 --> Jul 2024
- | prednisone delayed-release tablet / Generic mfg.
🎞️Se trata de una herramienta de imágenes de #InteligenciaArtificial autónoma denominada #ChestLink. 🔬Es capaz de analizar infinidad de imágenes de rayos X del torso de diferentes pacientes. (Twitter) - Nov 4, 2022
- | Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute
Trial completion date: Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Nov 4, 2022
P1/2, N=50, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Jul 2022 --> Jul 2024 | Trial primary completion date: Jul 2022 --> Jul 2024 Trial completion date: Dec 2024 --> Dec 2023
- ||| prednisone delayed-release tablet / Generic mfg.
Queres saber como se hace una ablacion de FA sin utilizar rayos ? @MRazminia te lo cuenta paso a paso en el #CAA2022 (Twitter) - Nov 2, 2022
- | prednisone delayed-release tablet / Generic mfg.
Trial completion, Metastases: Cryotherapy in Treating Patients With Primary Stage I Non-Small Cell Lung Cancer or Lung Metastasis (clinicaltrials.gov) - Nov 1, 2022
P1, N=9, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
Trial completion date: Dec 2024 --> Dec 2023 Active, not recruiting --> Completed
- | Zynlonta (loncastuximab tesirine-lpyl) / Overland ADCT BioPharma, Rituxan (rituximab) / Roche
New P2 trial: Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Oct 31, 2022
P2, N=24, Not yet recruiting, Sponsor: Joseph Tuscano
- ||| prednisone delayed-release tablet / Generic mfg.
Clinical: 1a reunión del comite multidisciplinar de patología intersticial. conseguimos empezar. Gracias @neumobierzo #rayos #ap #reuma #hado #interna #paliativos #farmacia #paliativos @masuvalor #anajimenez @mariamolinao @CatedraVida @BoehringerES @socalpar @SeparRespira #HospitalUBierzo (Twitter) - Oct 25, 2022
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment closed, Checkpoint inhibition, Checkpoint block, Metastases: Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers (clinicaltrials.gov) - Oct 25, 2022
P1, N=16, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Suspended --> Active, not recruiting
- ||| itacitinib (INCB039110) / Incyte
Trial completion date, Trial primary completion date: GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (clinicaltrials.gov) - Oct 19, 2022
P2/3, N=155, Active, not recruiting, Sponsor: Incyte Corporation
Suspended --> Active, not recruiting Trial completion date: Apr 2024 --> Mar 2023 | Trial primary completion date: Apr 2024 --> Mar 2023
- | Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma, Talzenna (talazoparib) / Pfizer
Enrollment open, Enrollment change: Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer (clinicaltrials.gov) - Oct 10, 2022
P2, N=70, Recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Apr 2024 --> Mar 2023 | Trial primary completion date: Apr 2024 --> Mar 2023 Active, not recruiting --> Recruiting | N=20 --> 70
- | Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma, Talzenna (talazoparib) / Pfizer
Enrollment closed, Enrollment change: Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer (clinicaltrials.gov) - Sep 30, 2022
P2, N=20, Active, not recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Recruiting | N=20 --> 70 Recruiting --> Active, not recruiting | N=70 --> 20
- || Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Enrollment closed: Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 23, 2022
P1, N=24, Active, not recruiting, Sponsor: University of Washington
Recruiting --> Active, not recruiting | N=70 --> 20 Recruiting --> Active, not recruiting
- | Sarclisa (isatuximab-irfc) / Sanofi
Trial completion date, Trial primary completion date: Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma (clinicaltrials.gov) - Sep 22, 2022
P1/2, N=37, Recruiting, Sponsor: Washington University School of Medicine
Recruiting --> Active, not recruiting Trial completion date: Oct 2028 --> Oct 2029 | Trial primary completion date: Oct 2023 --> Oct 2024
- | Darzalex (daratumumab) / J&J
Trial completion date, Trial primary completion date: A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma (clinicaltrials.gov) - Sep 14, 2022
P1, N=15, Recruiting, Sponsor: AIDS Malignancy Consortium
Trial completion date: Oct 2028 --> Oct 2029 | Trial primary completion date: Oct 2023 --> Oct 2024 Trial completion date: Aug 2024 --> Aug 2027 | Trial primary completion date: Aug 2022 --> Jul 2025
- | Onureg (azacitidine oral) / BMS
Trial suspension: Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Sep 13, 2022
P2/3, N=422, Suspended, Sponsor: National Cancer Institute (NCI)
Trial completion date: Aug 2024 --> Aug 2027 | Trial primary completion date: Aug 2022 --> Jul 2025 Recruiting --> Suspended
- | Venclexta (venetoclax) / Roche, AbbVie, DS-1594 / Daiichi Sankyo
Enrollment closed, Enrollment change, Combination therapy: DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 8, 2022
P1/2, N=20, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Suspended Recruiting --> Active, not recruiting | N=122 --> 20